Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05921903 · ClinicalTrials.gov registry record · Phase 2

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

A Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
386
Enrollment target
20
Study locations

NCT05921903 is a Phase 2 study of Respiratory Syncytial Virus Infections that has completed, run by GlaxoSmithKline. The registered enrollment target is 386 participants, below the 1,073-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05921903, a Phase 2 study of Respiratory Syncytial Virus Infections, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
386 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune response.

Conditions Studied

Respiratory Syncytial Virus Infections

Interventions

  • BIOLOGICAL RSVPreF3 OA Investigational Vaccine

Study Locations (20)

New York

  • GSK Investigational Site - New York
  • GSK Investigational Site - New York

Queensland

  • GSK Investigational Site - Birtinya
  • GSK Investigational Site - Herston

Ontario

  • GSK Investigational Site - London
  • GSK Investigational Site - Toronto

Arizona

  • GSK Investigational Site - Phoenix

Illinois

  • GSK Investigational Site - Chicago

Kentucky

  • GSK Investigational Site - Lexington

Minnesota

  • GSK Investigational Site - Minneapolis

Missouri

  • GSK Investigational Site - St Louis

Trial Details

FieldValue
Enrollment Target 386 participants
Start Date 2023-07-28
Est. Completion 2025-05-16
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05921903

The ClinicalTrials.gov registry entry for NCT05921903 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,073-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (64% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 1 intervention - of which RSVPreF3 OA Investigational Vaccine is the first listed.

NCT05921903 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New York, Queensland, Ontario.

Frequently Asked Questions

What is clinical trial NCT05921903 about?

NCT05921903 is a clinical study titled "A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above". The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune response.

What is the current status of trial NCT05921903?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2023-07-28. Estimated completion is 2025-05-16.

What conditions does trial NCT05921903 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.

What interventions are being tested in trial NCT05921903?

The interventions under investigation include: RSVPreF3 OA Investigational Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT05921903?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05921903 being conducted?

This trial has 20 study locations across Arizona, Illinois, Kentucky, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Respiratory Syncytial Virus Infections

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.